Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From 3SBio Inc.

Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows

Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.

China Deals

First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns

Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.

Biosimilars Commercial

Cross-Strait Taiwan Tensions, COVID, And Clinical Trials: An Interview With TLC President Yeh

A recent survey showed healthcare as among the sectors US companies were most concerned about amid the ongoing China-US tensions over Taiwan. But how do biotech firms on the island itself view the current situation? We spoke to the president of one amid Taiwan’s imminent reopening.

Strategy Policy

TLC President On COVID, Cross-Strait Taiwan Tensions

A recent survey showed healthcare as the sector US public companies were most concerned about (after semiconductors) amid the ongoing China-US tensions over Taiwan. But how do biotech firms in Taiwan itself view the current situation? Scrip spoke to the president of one of the most innovative and active companies in the sector, amid the island’s imminent reopening to the world after over two long years under pandemic restrictions.

Policy Risk Management
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Decade Sunshine Limited
    • Decade Sunshine Merger Sub
    • Hongkong Sansheng
    • Shenyang Sunshine Pharmaceutical Company Ltd
    • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
    • Zhejiang Wansheng Pharmaceutical Co., Ltd
    • Sirton Pharmaceuticals SpA
    • Sansheng Guojian Pharmaceutical (Shanghai) Co td
UsernamePublicRestriction

Register